Last Updated: October 1, 2026

Investigational Drug Information for TEW-7197


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for TEW-7197?

TEW-7197 is an investigational drug.

There have been 15 clinical trials for TEW-7197. The most recent clinical trial was a Phase 1 trial, which was initiated on November 22nd 2019.

The most common disease conditions in clinical trials are Adenocarcinoma, Pancreatic Neoplasms, and Neoplasms. The leading clinical trial sponsors are MedPacto, Inc., AstraZeneca, and Samsung Medical Center.

There are ninety-seven US patents protecting this investigational drug and seventy international patents.

Recent Clinical Trials for TEW-7197
TitleSponsorPhase
Assessing Clinical Trial Outcome of Patients With Relapsed/Refractor Metastatic Osteosarcoma in Adolescents and AdultsMedPacto, Inc.Phase 1/Phase 2
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerJennifer Eva SelfridgePhase 1
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionAstraZenecaPhase 2

See all TEW-7197 clinical trials

Clinical Trial Summary for TEW-7197

Top disease conditions for TEW-7197
Top clinical trial sponsors for TEW-7197

See all TEW-7197 clinical trials

US Patents for TEW-7197

Glossary
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TEW-7197 ⤷  Start Trial Pharmaceutical composition for preventing or treating cancer and method using thereof Medpacto Inc ⤷  Start Trial
TEW-7197 ⤷  Start Trial Antisense-oligonucleotides as inhibitors of TGF-R signaling NeuroVision Pharma GmbH (Grunwald, DE) ⤷  Start Trial
TEW-7197 ⤷  Start Trial 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same Frequency Therapeutics, Inc. (Woburn, MA) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links